Page 25 - Project Orbis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer News provided by Share this article Share this article SILVER SPRING, Md., April 16, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. "Today's approval is the first treatment in more than ...

FDA approves immunotherapy for first-line treatment of advanced gastric cancer Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. Today's approval is the first treatment in more than a decade to show a survival benefit for patients with advanced or metastatic gastric cancer who are bei...

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study – – Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted full approval to Trodelvy ® for adult patients with … Trodelvy Significantly Redu...

(0) NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs. The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). The primary endpoint is the Combined Response Index for Systemic Sclerosis (CRISS)...

BridgeBio, Helsinn Ink Up-to-$2.4B Infigratinib Partnership April 1, 2021 BridgeBio Pharma will join with Swiss pharma Helsinn Group to co-develop and commercialize infigratinib (BGJ398) in oncology and other indications except achondroplasia and other skeletal dysplasias, through a partnership that could generate up to approximately $2.45 billion for BridgeBio. [Helsinnn Group] Share BridgeBio Pharma will join with Swiss pharma Helsinn Group to co-develop and commercialize infigratinib (BGJ398) in oncology and other indications except achondroplasia and other skeletal dysplasias, through a p...